Eli Lilly and Company (NYSE: LLY) reported interim findings from the ADlong Phase 3b study showing its drug EBGLYSS maintained efficacy for up to four years in patients with moderate-to-severe atopic dermatitis. The results were presented at the American Academy of Dermatology Annual Meeting in Denver.

According to the study data, 94% of patients achieved EASI-75, a measure indicating 75% reduction in disease severity from baseline. Additionally, 75% of patients reached EASI-90, representing 90% improvement, while 78% experienced significant itch relief with a Pruritus Numeric Rating Scale score of 4 or lower.

The open-label extension study included 174 patients who received EBGLYSS 250 mg every four weeks. Most patients, 77%, used EBGLYSS as monotherapy, and 80% achieved results without requiring topical corticosteroids during the treatment period.

EBGLYSS is an interleukin-13 inhibitor that targets IL-13 signaling. The drug received approval in the United States, Japan, and Canada in 2024, and in the European Union in 2023 for treating moderate-to-severe atopic dermatitis in adults and children 12 years and older weighing at least 40 kg.

The safety profile remained consistent with previous studies, with conjunctivitis reported in 6.9% of patients and injection-site reactions in 0.6% as the most common treatment-related adverse events. The majority of adverse events were classified as mild or moderate and did not lead to treatment discontinuation.

The ADlong study will continue for an additional year of treatment. Lilly holds exclusive development and commercialization rights for EBGLYSS in the United States and markets outside Europe, while partner Almirall has licensed rights for European markets.